



NEONATAL

ALBUMIN (HUMAN) 4%

This document should be read in conjunction with this [DISCLAIMER](#)




Highly Restricted: Requires neonatologist approval before commencing

⚠ HIGH RISK Medication

There are 2 strengths of Albumin (Human) available, Albumin 4% and Albumin 20%.
Incorrect product selection could lead to severe circulatory overload.

| | |
|-----------------------------------|---|
| Presentation | Vial: 40mg/mL (4%) 50mL |
| Classification | Albumin is manufactured from pooled human plasma. Please read with Transfusion Medicine Protocols – Albumin 4% . Written consent to blood products required. Refer to Transfusion Medicine Protocol – Blood Products (Neonates) . |
| Indication | Hypovolaemia (Plasma Expander) |
| Dose | <u>Hypovolaemia</u> IV: 0.5g – 1g/kg/dose (12.5mL – 25 mL/kg) |
| Monitoring | Temperature, pulse, respiration, blood pressure, urine output, electrolyte levels. Observe for signs of hypervolemia, pulmonary oedema and cardiac failure. Refer to Transfusion Medicine Protocols – Albumin 4% . |
| Guidelines & Resources | Transfusion Medicine Protocols – Albumin 4% . |
| Compatible Fluids | Sodium chloride 0.9%, Glucose 10%, Glucose 5% and glucose/saline solutions. |
| Preparation | Albumin is a clear or slightly opalescent solution. If it appears cloudy, do not use. Discard any unused solution. Do not use the product if it appears turbid. |

| | | |
|--------------------------|---|---|
| Administration | <p>Intravenous infusion:</p> <p>Infuse over 5-10 minutes. Faster infusion rates may be clinically necessary, refer to Neonatologist.</p> <p>Refer to Transfusion Medicine Protocols – Albumin 4%.</p> <p>Flush with sodium chloride 0.9% after infusion is complete</p> | |
| Adverse Reactions | <p>Common</p> <p>Serious</p> | <p>Chills, fever, vomiting, urticaria</p> <p>Hypertension, vascular overload causing pulmonary oedema, cardiac failure, Intraventricular haemorrhage, anaphylaxis</p> |
| Storage | Store below 30 °C. Do not freeze. Protect from light. | |
| Interactions | Water for injections – risk of reduction in tonicity. | |
| Notes | <p>Albumin should be administered through a standard IV giving set</p> <p>Do not ‘piggy-back’ onto other lines</p> <p>Neonatologist to determine rate of infusion</p> | |
| References | <p>Society of Hospital Pharmacists of Australia. Albumin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Mar 15]. Available from: http://aidh.hcn.com.au</p> <p>Truven Health Analytics. Albumin(Human). In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [Cited 2018 Mar 15]. Available from: https://neofax.micromedexsolutions.com/</p> <p>Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2017. 2,401 p75.</p> <p>Zenk KE. Neonatology: management, procedures, on-call problems, diseases, and drugs. Gomella TL, Cunningham MD, Eyal FG, editors. New York: McGraw-Hill; 2009.</p> <p>Shann F. Drug doses. Seventeenth ed. Parkville (Victoria): Collective P/L; 2017.</p> | |

| | | | |
|---|---|-------------------|------------|
| Document owner: | Head of Department - Neonatology | | |
| Author / Reviewer: | KEMH & PCH Pharmacy / Neonatology Directorate | | |
| Date first issued: | February 2013 | Version: | 3.1 |
| Last reviewed: | March 2019 | Next review date: | March 2021 |
| Endorsed by: | Neonatal Directorate Management Group | Date: | March 2019 |
| Standards Applicable: | NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety; | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website. | | | |

© Department of Health Western Australia 2018